Astellas Pharma announced a pharma alliance with an investigator at Harvard Medical School focused on discovering the pathologic mechanism for retinitis pigmentosa and identification of new therapeutic targets.

Astellas and Harvard will work with the aim to provide a new treatment option with a view of a gene therapy, to retinitis pigmentosa patients who have difficulty maintaining good vision.

This collaborative research will be led by Constance L. Cepko, Ph. D., Professor of Genetics and of Ophthalmology at Harvard, who is also an investigator of the Howard Hughes Medical Institute, and is a world-renowned authority on ophthalmology and gene therapy.

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with Astellas Pharma

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter